VIVUS,INC. (NASDAQ:VVUS) Files An 8-K Regulation FD Disclosure

ME Staff 8-k
-
0
VIVUS,INC. (NASDAQ:VVUS) Files An 8-K Regulation FD Disclosure

VIVUS,INC. (NASDAQ:VVUS) Files An 8-K Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure

On September26, 2018, VIVUS,Inc. (the “Company”) issued a press release titled “VIVUS Regains Compliance with Nasdaq Listing Requirements.”

A copy of the press release is attached as Exhibit99.1 to this Current Report on Form8-K. The information in this Item 7.01 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, or incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

Item 8.01. Other Events

On September25, 2018, the Company received notification from the staff (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) that the Company regained compliance with Listing Rule5550(a)(2)(the “Rule”), which requires a minimum bid price of $1.00 per share. The Staff notified the Company that it has regained compliance with the Ruleand it has closed the matter. The Company is now fully compliant with all Nasdaq listing rules.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits.

SIGNATURES


VIVUS INC Exhibit
EX-99.1 2 a18-35082_1ex99d1.htm EX-99.1 Exhibit 99.1     VIVUS Regains Compliance with Nasdaq Listing Requirements   CAMPBELL,…
To view the full exhibit click here

About VIVUS,INC. (NASDAQ:VVUS)

VIVUS, Inc. is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company has completed the Phase II studies of Qsymia for the indication of Obstructive Sleep Apnea (OSA) and diabetes. Its Qsymia is available in over 40,000 certified retail pharmacies across the country. Its STENDRA is also approved by the European Commission (EC), under the name, SPEDRA, for the treatment of ED in the Europe. The United States Food and Drug Association approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.